"The retasking of CCR5 inhibitors for cancer prevention and treatment of metastatic cancer leverages the substantial prior clinical experience with these compounds and their known safety profiles in patients with HIV. Several additional agents, when combined with CCR5 inhibitors have shown promise in preclinical studies including anti-IL-6 receptor antibody for TNBC and PDL-1 inhibitors in gastric and colon cancer. The finding that CCR5 inhibitors enhance cancer cell killing mediated by radiation and DNA-damaging chemotherapeutic agents (5) suggests the potential for combining these biological agents with chemotherapeutics in order to potentially reduce the dose-dependent side-effects of chemotherapy."
News 
Market Data 
Discover 
AI
